Mounjaro, Zepbound May Lower Risk of Eye Disease in People With Diabetes

**Reducing the Risk of Diabetic Retinopathy with Tirzepatide** Tirzepatide, a medication used to manage type 2 diabetes, may also help lower the risk of diabetic retinopathy, a complication that can lead to vision loss.

**Reducing the Risk of Diabetic Retinopathy with Tirzepatide**

Tirzepatide, a medication used to manage type 2 diabetes, may also help lower the risk of diabetic retinopathy, a complication that can lead to vision loss.

Diabetic retinopathy occurs when high blood sugar levels damage the blood vessels in the retina at the back of the eye. It is one of several eye diseases associated with diabetes, including cataracts and glaucoma.

A recent study published in Ophthalmology found that GLP-1 weight loss drugs like Mounjaro and Zepbound, which contain tirzepatide, may reduce the risk of developing new diabetic retinopathy or progressing to more severe stages of the disease in people with type 2 diabetes.

According to Dr. Szilard Kiss, lead author of the study, "The findings suggest that individuals with diabetic retinopathy may have a reduced risk of requiring more eye treatments with lasers or injections while taking tirzepatide."

The researchers analyzed electronic health records from 174,000 people across 70 health systems in the United States and found that after one year of treatment, patients taking tirzepatide had a lower risk of worsening diabetic retinopathy or related complications compared to those using lifestyle interventions.

For example, incident mild non-proliferative diabetic retinopathy occurred in 0.49% of tirzepatide patients compared with 1.2% of the lifestyle intervention group.

This study provides new hope for individuals living with type 2 diabetes and diabetic retinopathy. If you have questions or concerns about your eye health, please contact our clinic to schedule an appointment with one of our experienced ophthalmologists.

Learn more about hair transplant at Rubenhair clinic.